|
 |
Oxsoralen-UltraThis page contains recent news articles, when available, and an overview of Oxsoralen-Ultra but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.Overview: Oxsoralen-Ultra (when available) Methoxsalen selectively inhibits the synthesis of deoxyribonucleic acid (DNA). The guanine and cytosine content correlates with the degree of Methoxsalen-induced cross-linking. At high concentrations of the drug, cellular RNA and protein synthesis are also suppressed. For the treatment of psoriasis and vitiligo Mechanism Of Action: after activationm it binds preferentially to the guanine and cytosine moieties of DNA, leading to cross-linking of DNA, thus inhibiting DNA synthesis and function. News Articles on Methoxsalen … Sales & Marketing Responsibility of Oxsoralen-Ultra(R) from... - Feb 7, 2007 CHARLESTON, SC, Feb. 7 /PRNewswire/ -- JSJ Pharmaceuticals today announced a multi-year agreement under which it has assumed from Valeant Pharmaceuticals ... Genetic Engineering News - Genetic Engineering News (press release) Merger and Acquisition Scenario - Sep 6, 2008 Buyer:, Valeant Pharmaceuticals International (VRX), Last Price:, 18.56, Market Cap.:, 1.63B. Target:, ZymoGenetics, Inc. (ZGEN), Last Price:, 8.50 ... $250.00 - Revere Reports - Revere … Sales & Marketing Responsibility of Oxsoralen-Ultra(R) from Vale - Feb 7, 2007 JSJ Pharmaceuticals Assumes Sales & Marketing Responsibility of Oxsoralen-Ultra(R) from Valeant Pharmaceuticals International. from PR Newswire. Pay-Per-View - PR Newswire - HighBeam Research Merger and Acquisition Scenario - Sep 6, 2008 Buyer:, Valeant Pharmaceuticals International (VRX), Last Price:, 18.56, Market Cap.:, 1.63B. Target:, Progenics Pharmaceuticals, Inc. (PGNX), Last Price: ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Oct 21, 2006 Buyer:, Valeant Pharmaceuticals International (VRX), Last Price:, 19.78, Market Cap.:, 1.84B. Target:, New River Pharmaceuticals, Inc. (NRPH), Last Price: ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Oct 20, 2007 Buyer:, Adams Respiratory Therapeutics, Inc. (ARXT), Last Price:, 39.21, Market Cap.:, 1.41B. Target:, Valeant Pharmaceuticals International (VRX) ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Sep 6, 2008 Buyer:, Valeant Pharmaceuticals International (VRX), Last Price:, 18.56, Market Cap.:, 1.63B. Target:, Halozyme Therapeutics, Inc. (HALO), Last Price:, 7.52 ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Mar 1, 2008 Target (Total: 33). Efudex (Fluorouracil); 8-MOP (Methoxsalen); Oxsoralen-Ultra (Methoxsalen); Eldoquin (Hydroquinone) ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Jun 16, 2007 Buyer:, MedImmune, Inc. (MEDI), Last Price:, 57.94, Market Cap.:, 13.84B. Target:, Valeant Pharmaceuticals International (VRX), Last Price:, 17.39 ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Sep 6, 2008 Buyer:, Valeant Pharmaceuticals International (VRX), Last Price:, 18.56, Market Cap.:, 1.63B. Target:, Rigel Pharmaceuticals, Inc. (RIGL), Last Price: ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Oct 6, 2007 Buyer:, Valeant Pharmaceuticals International (VRX), Last Price:, 15.79, Market Cap.:, 1.45B. Target:, Adams Respiratory Therapeutics, Inc. (ARXT) ... $250.00 - Revere Reports - Revere Psoriasis Drug May Help People Quit Smoking - Aug 8, 2005 By Miranda Hitti. Researchers may have figured out how a drug called methoxsalen may help smokers quit smoking. Methoxsalen blocks nicotine breakdown, ... FOXNews Merger and Acquisition Scenario - Aug 30, 2008 Buyer:, Auxilium Pharmaceuticals, Inc. (AUXL), Last Price:, 39.31, Market Cap.:, 1.63B. Target:, Valeant Pharmaceuticals International (VRX), Last Price: ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Sep 6, 2008 Buyer:, Valeant Pharmaceuticals International (VRX), Last Price:, 18.56, Market Cap.:, 1.63B. Target:, Incyte Corporation (INCY), Last Price:, 9.92 ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Sep 6, 2008 Buyer:, Valeant Pharmaceuticals International (VRX), Last Price:, 18.56, Market Cap.:, 1.63B. Target:, InterMune, Inc. (ITMN), Last Price:, 18.53 ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Sep 6, 2008 Buyer:, Valeant Pharmaceuticals International (VRX), Last Price:, 18.56, Market Cap.:, 1.63B. Target:, VIVUS, Inc. (VVUS), Last Price:, 8.59, Market Cap. ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Sep 6, 2008 Buyer:, Valeant Pharmaceuticals International (VRX), Last Price:, 18.56, Market Cap.:, 1.63B. Target:, NPS Pharmaceuticals, Inc. (NPSP), Last Price:, 8.65 ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Sep 6, 2008 Buyer:, Valeant Pharmaceuticals International (VRX), Last Price:, 18.56, Market Cap.:, 1.63B. Target:, Arena Pharmaceuticals, Inc. (ARNA), Last Price:, 5.80 ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Oct 21, 2006 Buyer:, Valeant Pharmaceuticals International (VRX), Last Price:, 19.78, Market Cap.:, 1.84B. Target:, Andrx Corporation (ADRX), Last Price:, 24.72 ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Mar 11, 2006 Buyer:, Acambis plc (ADR) (ACAM), Last Price:, 7.21, Market Cap.:, 3.87B. Target:, Valeant Pharmaceuticals International (VRX), Last Price:, 19.50 ... $250.00 - Revere Reports - Revere Trade Alert for Valeant Pharmaceuticals International. - Jun 12, 2007 Valeant Pharmaceuticals International, a specialty pharmaceutical company, engages in the development, manufacture, and marketing of a range of ... Free with registration - M2 Presswire - AccessMyLibrary.com New Help To Quit Smoking - Aug 8, 2008 By Joel Arak. (WebMD) Researchers may have figured out how a drug called methoxsalen may help smokers quit smoking. Methoxsalen blocks nicotine breakdown, ... CBS News Merger and Acquisition Scenario - Sep 23, 2006 Buyer:, Valeant Pharmaceuticals International (VRX), Last Price:, 19.54, Market Cap.:, 1.82B. Target:, Warner Chilcott Holdings Company, Ltd. (WCRX) ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Dec 16, 2006 Buyer:, Altana AG (ADR) (AAA), Last Price:, 60.77, Market Cap.:, 8.25B. Target:, Valeant Pharmaceuticals International (VRX), Last Price:, 17.09 ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Nov 25, 2006 Buyer:, Schering AG (ADR) (SHR), Last Price:, 120.31, Market Cap.:, 22.96B. Target:, Valeant Pharmaceuticals International (VRX), Last Price:, 16.64 ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Oct 20, 2007 Buyer:, Medicis Pharmaceutical Corporation (MRX), Last Price:, 27.00, Market Cap.:, 1.52B. Target:, Valeant Pharmaceuticals International (VRX), Last Price: ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Dec 16, 2006 Buyer:, KOS Pharmaceuticals, Inc. (KOSP), Last Price:, 78.00, Market Cap.:, 3.72B. Target:, Valeant Pharmaceuticals International (VRX), Last Price:, 17.09 ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Aug 19, 2006 Buyer:, Protherics PLC (ADR) (PTIL), Last Price:, 14.24, Market Cap.:, 3.45B. Target:, Valeant Pharmaceuticals International (VRX), Last Price:, 19.00 ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Apr 28, 2007 Buyer:, Valeant Pharmaceuticals International (VRX), Last Price:, 18.34, Market Cap.:, 1.74B. Target:, Alexion Pharmaceuticals, Inc. (ALXN), Last Price: ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Nov 4, 2006 Buyer:, Andrx Corporation (ADRX), Last Price:, 25.00, Market Cap.:, 1.85B. Target:, Valeant Pharmaceuticals International (VRX), Last Price:, 17.47 ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Jun 23, 2007 Buyer:, Valeant Pharmaceuticals International (VRX), Last Price:, 16.83, Market Cap.:, 1.60B. Target:, Myriad Genetics, Inc. (MYGN), Last Price:, 36.25 ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Oct 20, 2007 Buyer:, Theravance, Inc. (THRX), Last Price:, 25.46, Market Cap.:, 1.54B. Target:, Valeant Pharmaceuticals International (VRX), Last Price:, 14.62 ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Oct 14, 2006 Buyer:, Valeant Pharmaceuticals International (VRX), Last Price:, 19.67, Market Cap.:, 1.83B. Target:, ICOS Corporation (ICOS), Last Price:, 27.08 ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Aug 19, 2006 Buyer:, Johnson & Johnson (JNJ), Last Price:, 64.42, Market Cap.:, 188.43B. Target:, Valeant Pharmaceuticals International (VRX), Last Price:, 19.00 ... $250.00 - Revere Reports - Revere Press Release: Trade Alert for Valeant Pharmaceuticals International.... - Jun 12, 2007 Trade Alert for Valeant Pharmaceuticals International. from M2 Presswire. Highbeam Research – FREE Trial. Pay-Per-View - M2 Presswire - HighBeam Research Merger and Acquisition Scenario - Oct 20, 2007 Buyer:, MGi Pharma, Inc. (MOGN), Last Price:, 31.05, Market Cap.:, 2.48B. Target:, Valeant Pharmaceuticals International (VRX), Last Price:, 14.62 ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Sep 6, 2008 Efudex (Fluorouracil); 8-MOP (Methoxsalen); Oxsoralen-Ultra (Methoxsalen); Eldoquin (Hydroquinone). Target. Twinject Epinephrine Auto-Injector ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Aug 25, 2007 Buyer:, Valeant Pharmaceuticals International (VRX), Last Price:, 16.18, Market Cap.:, 1.49B. Target:, Pharmion Corporation (PHRM), Last Price:, 38.64 ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - May 19, 2007 Buyer:, Merck Serono S.A. (ADR) (SRA), Last Price:, 22.72, Market Cap.:, 13.92B. Target:, Valeant Pharmaceuticals International (VRX), Last Price:, 15.44 ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Sep 13, 2008 Buyer:, APP Pharmaceuticals, Inc. (APPX), Last Price:, 23.70, Market Cap.:, 3.81B. Target:, Valeant Pharmaceuticals International (VRX), Last Price:, 18.87 ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - May 3, 2008 Buyer:, Chattem Inc. (CHTT), Last Price:, 66.74, Market Cap.:, 1.28B. Target:, Valeant Pharmaceuticals International (VRX), Last Price:, 13.36, Market Cap. ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Sep 6, 2008 Buyer:, Valeant Pharmaceuticals International (VRX), Last Price:, 18.56, Market Cap.:, 1.63B. Target:, Par Pharmaceutical Companies, Inc. (PRX), Last Price: ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - May 17, 2008 Buyer:, Millennium Pharmaceuticals, Inc. (MLNM), Last Price:, 24.97, Market Cap.:, 8.17B. Target:, Valeant Pharmaceuticals International (VRX), Last Price: ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - May 3, 2008 Buyer:, PDL BioPharma Inc. (PDLI), Last Price:, 13.82, Market Cap.:, 1.63B. Target:, Valeant Pharmaceuticals International (VRX), Last Price:, 13.36 ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Aug 16, 2008 Buyer (Total: 30). Efudex (Fluorouracil); Oxsoralen-Ultra (Methoxsalen); 8-MOP (Methoxsalen); Eldoquin (Hydroquinone) ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - May 3, 2008 Buyer:, K-V Pharmaceutical Company (KV/A), Last Price:, 25.16, Market Cap.:, 1.26B. Target:, Valeant Pharmaceuticals International (VRX), Last Price:, 13.36 ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Aug 2, 2008 Buyer:, Valeant Pharmaceuticals International (VRX), Last Price:, 17.14, Market Cap.:, 1.53B. Target:, Meldex International Plc (MLGGY), Last Price:, 7.20 ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Sep 6, 2008 Buyer:, Valeant Pharmaceuticals International (VRX), Last Price:, 18.56, Market Cap.:, 1.63B. Target:, Sangamo Biosciences, Inc. (SGMO), Last Price:, 9.53 ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Apr 5, 2008 Buyer:, Merck & Co., Inc. (MRK), Last Price:, 40.00, Market Cap.:, 87.37B. Target:, Valeant Pharmaceuticals International (VRX), Last Price:, 13.55 ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Jul 12, 2008 Target (Total: 30). Efudex (Fluorouracil); Oxsoralen-Ultra (Methoxsalen); 8-MOP (Methoxsalen); Eldoquin (Hydroquinone) ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Jul 26, 2008 Buyer:, Meldex International Plc (MLGGY), Last Price:, 7.80, Market Cap.:, 1.64B. Target:, Valeant Pharmaceuticals International (VRX), Last Price:, 17.95 ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Sep 6, 2008 Buyer:, Valeant Pharmaceuticals International (VRX), Last Price:, 18.56, Market Cap.:, 1.63B. Target:, Eurand N.V. (EURX), Last Price:, 17.55, Market Cap. ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Sep 6, 2008 Buyer:, Valeant Pharmaceuticals International (VRX), Last Price:, 18.56, Market Cap.:, 1.63B. Target:, Caraco Pharmaceutical Laboratories Ltd. (CPD) ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Mar 22, 2008 Buyer:, Axcan Pharma Inc. (USA) (AXCA), Last Price:, 23.34, Market Cap.:, 1.29B. Target:, Valeant Pharmaceuticals International (VRX), Last Price:, 13.13 ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Sep 13, 2008 Buyer:, Roche Holding Ltd. (ADR) (RHHBY), Last Price:, 84.25, Market Cap.:, 145.34B. Target:, Valeant Pharmaceuticals International (VRX), Last Price: ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Mar 8, 2008 Buyer:, Pharmion Corporation (PHRM), Last Price:, 72.32, Market Cap.:, 2.71B. Target:, Valeant Pharmaceuticals International (VRX), Last Price:, 13.02 ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Feb 16, 2008 Buyer:, Alnylam Pharmaceuticals, Inc. (ALNY), Last Price:, 33.75, Market Cap.:, 1.38B. Target:, Valeant Pharmaceuticals International (VRX), Last Price: ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Sep 6, 2008 Buyer:, Valeant Pharmaceuticals International (VRX), Last Price:, 18.56, Market Cap.:, 1.63B. Target:, Prestige Brands Holdings, Inc. (PBH), Last Price: ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Oct 11, 2008 Target (Total: 30). Efudex (Fluorouracil); Oxsoralen-Ultra (Methoxsalen); 8-MOP (Methoxsalen); Eldoquin (Hydroquinone) ... $250.00 - Revere Reports - Revere Brand Names/Synonyms: Oxsoralen-Ultra is also known by the following brand names and/or synonymsAmmodin; Ammoidin; Meladinin; Meladinine; Meladoxen; Meloxine; Methoxa-Dome; Methoxalen; Methoxaten; Methoxsalen; New-Meladinin; Oxoralen; Oxsoralen; Oxsoralen Lotion; Oxsoralen-Ultra; Oxypsoralen; Proralone-Mop; Psoralen-Mop; Puvalen; Puvamet; Ultra Mop; Ultramop Lotion; Uvadex; Xanthotoxin; Xanthotoxine; Xanthoxin; Zanthotoxin Drug Category: Oxsoralen-Ultra is categorized under the following by the FDA: Antineoplastic Agents; Pigmenting Agents; ATC:D05AD02; ATC:D05BA02 Dosage Forms: LIQUID Absorption: Not Available Interactions: [an error occurred while processing this directive] Chemical IUPAC Name: Not Available |
|
Health Home | Conditions | Cancer | Medications | Surgery | Vaccines The Cancer News Network
COPYRIGHT 2009 CANCERNEWSNETWORK | Privacy |